NCT03563248 2025-10-01
Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
Clinical Trials
11 trialsNCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT02676349 2023-09-28
Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)
Institut de Cancérologie de Lorraine
Phase 2 Active not recruiting
NCT05083247 2023-05-23
STEREOPAC
Erasme University Hospital
Phase 2 Recruiting
NCT03199144 2022-06-23
CKPancreas
Centre Francois Baclesse, Luxembourg
Phase 2 Withdrawn
NCT03891472 2019-11-13
Clinical Phase II Clinical Study Evaluating the Toxicity and Efficacy of mFOLFIRINOX Associated With SBRT (Stereotactic Radiotherapy) in Patients With Unresectable Locally Advanced Pancreatic Cancer
Medical University of Silesia
Phase 2 Completed
NCT02301143 2019-03-20
LAPACT
Celgene
Phase 2 Completed
NCT00766636 2016-05-19
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00482625 2014-10-16
Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00003769 2014-09-10
Perillyl Alcohol Followed by Surgery in Treating Patients With Stage II or Stage III Pancreatic Cancer
Indiana University
Phase 2 Completed
NCT00487851 2013-04-12
Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer
Karolinska Institutet
Phase 2 Withdrawn